Literature DB >> 17322493

Sample pre-treatment determines the clinical usefulness of acid-labile subunit immunoassays in the diagnosis of growth hormone deficiency and acromegaly.

Katherine M Morrison1, Martin Bidlingmaier, Simone Stadler, Zida Wu, Lars Skriver, Christian J Strasburger.   

Abstract

OBJECTIVE: The usefulness of measuring the GH-dependent acid-labile subunit (ALS) in the management of GH deficiency (GHD) and acromegaly remains in question and is investigated in this study, comparing several different immunoassays for ALS.
METHOD: We compared the diagnostic accuracy of a commercially available polyclonal Ab-based ELISA with SDS pre-treatment (SDS-ELISA) with a monoclonal Ab-based immunofluorometric assay, using two unfolding methods (urea (UREA) and Glycine-HCl (Gly)). The corresponding molecular weight (MW) of ALS and IGFBP-3 immunoreactivity was determined. The clinical usefulness of each assay was examined in adult GH disorders.
RESULTS: ALS was lower in GHD and higher in acromegaly using all assays. In GHD, UREA had higher sensitivity and specificity than SDS-ELISA (59 and 69% versus 41 and 51% respectively). In acromegaly, sensitivity and specificity was 94 and 87% for UREA, 81 and 36% for Gly, and 44 and 44% for SDS-ELISA. After UREA, immunoreactivity for ALS and IGFBP-3 eluted at their predicted free MW using size-exclusion chromatography, whereas ALS immunoreactivity in SDS (300-600 kDa) and Gly (250-500 kDa) was at a high apparent MW consistent with aggregation.
CONCLUSION: The diagnostic accuracy of ALS varies with assay choice and pre-treatment modality. UREA, which results in migration of ALS at the expected MW on a sizing column, has the highest specificity and sensitivity. Thus, if measured in an assay in which ALS is unfolded without aggregation, ALS is a clinically highly useful parameter for the assessment of GH.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17322493     DOI: 10.1530/EJE-06-0592

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  3 in total

Review 1.  Advances in differential diagnosis and management of growth hormone deficiency in children.

Authors:  Camille Hage; Hoong-Wei Gan; Anastasia Ibba; Giuseppa Patti; Mehul Dattani; Sandro Loche; Mohamad Maghnie; Roberto Salvatori
Journal:  Nat Rev Endocrinol       Date:  2021-08-20       Impact factor: 43.330

2.  Endogenous estradiol may influence IGF-I levels in acromegalic women treated with pegvisomant.

Authors:  J Roemmler; M Bidlingmaier; J Schopohl
Journal:  Pituitary       Date:  2010       Impact factor: 4.107

3.  Soluble Alpha Klotho in Acromegaly: Comparison With Traditional Markers of Disease Activity.

Authors:  Júnia R O L Schweizer; Katharina Schilbach; Michael Haenelt; Alexandre V Giannetti; Mariana F Bizzi; Beatriz S Soares; Eduardo Paulino; Jochen Schopohl; Sylvère Störmann; Antônio Ribeiro-Oliveira; Martin Bidlingmaier
Journal:  J Clin Endocrinol Metab       Date:  2021-07-13       Impact factor: 5.958

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.